title: Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Di Benedetto
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tarantino
authors.forename: Roberto
authors.initials: R
authors.lastname: Montalti
authors.forename: Roberto
authors.initials: R
authors.lastname: Ballarin
authors.forename: Giuseppe
authors.initials: G
authors.lastname: D'Amico
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Berretta
authors.forename: Giorgio Enrico
authors.initials: GE
authors.lastname: Gerunda
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D011725:Pyridines